Members will vote next week on a hearing requirement involving the drug’s manufacturer.
The Senate Committee on Health, Education, Labor, and Pensions (HELP) announced that it will vote next week on whether or not to subpoena the president of Novo Nordisk, the company that manufactures the weight loss drug Ozempic.
Senator Bernie Sanders, who chairs the committee, said, “The HELP Committee has reached out time and time again to Novo Nordisk to request their voluntary attendance at a hearing to discuss why they are charging Americans up to 10 or 15 times more for the exact same product sold in other countries.”
“Unfortunately, despite all of our efforts, they have repeatedly denied our requests. We look forward to their presence at a hearing on July 10th,” he added.
The committee sent a letter to the president of Novo Nordisk in April, requesting an explanation for Ozempic’s $935.77 price per dose in the United States. This is significantly more than the company’s pricing in many other countries. Novo wrote back, faulting the U.S. healthcare system for the high price.
As the Lord Leads, Pray with Us…
- For Senator Sanders and members of the HELP Committee as they prepare to vote regarding a subpoena for the drug company’s president.
- For members of Congress as they investigate the high cost of prescription drugs.
Sources: Reuters, The Hill
